Starting this fall, the IU School of Medicine will offer a doctoral minor program on drug discovery and development, from bench to bedside. The goal of this degree minor is to provide prospective scientists and researchers the opportunity to jump-start their careers in biomedical science through learning how new medicines are discovered, developed and approved for human use. The program courses will be delivered by industry experts with many years of combined experience in the field. This minor will serve as a strong supplement to any biomedical program.
The 12-credit program will be offered by the Division of Clinical Pharmacology, and will be anchored by the newly-developed CLPH-D 501 (Discovering Novel Treatments) & 502 (Developing Clinically Approved Medicines). The program will take learners on a journey through the entire drug discovery and development process.
Six other elective credits are required. Dr. Andrew Dahlem, Chief of the Division of Clinical Pharmacology will be serving as the minor advisor for the program. Dr. Dahlem recently joined IUSM after a distinguished career at Eli Lilly and Company where he served in several leadership roles in drug discovery and development.